Compare Fubotv Inc (FUBO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Fubotv Inc trades at $8.84 (market cap $1.02B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 125× Fubotv Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FUBO | VRTX | |
|---|---|---|
Market Cap | $1.02B | $127.55B |
Volume | 978,631 | 1,487,944 |
Sector | Media | Health |
52-Week High | $48.96 | $557.96 |
52-Week Low | $8.09 | $407.37 |
Typical Hold Time | 35 Days | 120 Days |
Enterprise Value | $1.19B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.03, down 2.38% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M in 2025, representing a significant turnaround from previous losses. Recent developments include new sports streaming agreements with NHL teams and expanded partnerships with The Athletic, positioning the company for continued subscriber growth.
FUBO presents a compelling turnaround story with deep valuation discounts (P/E 2.43, P/S 0.19) and analyst consensus target of $63.38 suggesting 600%+ upside. However, risks include persistent cash flow challenges, high debt levels, and intense streaming competition. The Disney partnership and sports content expansion provide catalysts, but execution risk remains elevated given the company's history of losses.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
